Literature DB >> 7794775

Pearson's marrow/pancreas syndrome: haematological features associated with deletion and duplication of mitochondrial DNA.

O P Smith1, I M Hann, C E Woodward, M Brockington.   

Abstract

Pearson's marrow/pancreas syndrome (PS) is a rare, often fatal, disorder of infancy that is characterized by impaired bone marrow, exocrine pancreatic, hepatic and renal function. Large-scale rearrangements of mitochondrial DNA (mtDNA) are present in blood. We report a patient with PS who has predominantly impaired haemopoiesis manifesting as sideroblastic anaemia, vacuolization of bone marrow precursors, and neutropenia. 77% of bone marrow mtDNA was rearranged (64% deleted an 13% duplicated). We suggest that rearrangements of mtDNA should be sought in all infants presenting with sideroblastic anaemia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7794775     DOI: 10.1111/j.1365-2141.1995.tb05178.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Early onset of complete heart block in Pearson syndrome.

Authors:  S Rahman; J V Leonard
Journal:  J Inherit Metab Dis       Date:  2000-11       Impact factor: 4.982

Review 2.  Iron metabolism in erythroid cells and patients with congenital sideroblastic anemia.

Authors:  Kazumichi Furuyama; Kiriko Kaneko
Journal:  Int J Hematol       Date:  2017-11-14       Impact factor: 2.490

3.  Case Report: Clinical and Genetic Characteristics of Pearson Syndrome in a Chinese Boy and 139 Patients.

Authors:  Yanqin Ying; Yan Liang; Xiaoping Luo; Ming Wei
Journal:  Front Genet       Date:  2022-05-23       Impact factor: 4.772

4.  Mitochondrial DNA deletion and duplication in Kearns-Sayre Syndrome (KSS) with initial presentation as Pearson Marrow-Pancreas Syndrome (PMPS): Two case reports in Barranquilla, Colombia.

Authors:  Vanessa Sabella-Jiménez; Carlos Otero-Herrera; Carlos Silvera-Redondo; Pilar Garavito-Galofre
Journal:  Mol Genet Genomic Med       Date:  2020-10-08       Impact factor: 2.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.